253 related articles for article (PubMed ID: 27329245)
21. [Correlation between the expression of Pim-1 and androgen-deprivation therapy for prostate cancer].
Wang J; Quan CY; Chang WL; Shang ZQ; Jiang N; Li B; Niu YJ
Zhonghua Nan Ke Xue; 2015 Sep; 21(9):775-81. PubMed ID: 26552208
[TBL] [Abstract][Full Text] [Related]
22. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
Wright GL; Grob BM; Haley C; Grossman K; Newhall K; Petrylak D; Troyer J; Konchuba A; Schellhammer PF; Moriarty R
Urology; 1996 Aug; 48(2):326-34. PubMed ID: 8753752
[TBL] [Abstract][Full Text] [Related]
23. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
Damodaran S; Lang JM; Jarrard DF
J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
[TBL] [Abstract][Full Text] [Related]
24. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
25. The activation of OR51E1 causes growth suppression of human prostate cancer cells.
Maßberg D; Jovancevic N; Offermann A; Simon A; Baniahmad A; Perner S; Pungsrinont T; Luko K; Philippou S; Ubrig B; Heiland M; Weber L; Altmüller J; Becker C; Gisselmann G; Gelis L; Hatt H
Oncotarget; 2016 Jul; 7(30):48231-48249. PubMed ID: 27374083
[TBL] [Abstract][Full Text] [Related]
26. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
[TBL] [Abstract][Full Text] [Related]
27. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
28. Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin.
Yang B; Damodaran S; Khemees TA; Filon MJ; Schultz A; Gawdzik J; Etheridge T; Malin D; Richards KA; Cryns VL; Jarrard DF
Mol Cancer Ther; 2020 Nov; 19(11):2278-2287. PubMed ID: 32943543
[TBL] [Abstract][Full Text] [Related]
29. Actin alpha cardiac muscle 1 gene expression is upregulated in the skeletal muscle of men undergoing androgen deprivation therapy for prostate cancer.
Cheung AS; de Rooy C; Levinger I; Rana K; Clarke MV; How JM; Garnham A; McLean C; Zajac JD; Davey RA; Grossmann M
J Steroid Biochem Mol Biol; 2017 Nov; 174():56-64. PubMed ID: 28756295
[TBL] [Abstract][Full Text] [Related]
30. Stem cells in prostate cancer: resolving the castrate-resistant conundrum and implications for hormonal therapy.
Sharifi N; Kawasaki BT; Hurt EM; Farrar WL
Cancer Biol Ther; 2006 Aug; 5(8):901-6. PubMed ID: 16855379
[TBL] [Abstract][Full Text] [Related]
31. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
32. Prolonging androgen sensitivity in prostate cancer - a role for COX inhibitors?
Richards A; McGeechan K; Niknam M; Salomon R; Kurek C; Dong Q; Patel MI
ANZ J Surg; 2009 Sep; 79(9):641-7. PubMed ID: 19895521
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin derivative (smsDX) targets cellular metabolism in prostate cancer cells after androgen deprivation therapy.
Yan L; Xing Z; Guo Z; Fang Z; Jiao W; Guo X; Xu Z; Fang Z; Liu Z
PLoS One; 2013; 8(2):e55790. PubMed ID: 23409045
[TBL] [Abstract][Full Text] [Related]
34. Down-regulation of calcium/calmodulin-dependent protein kinase kinase 2 by androgen deprivation induces castration-resistant prostate cancer.
Shima T; Mizokami A; Miyagi T; Kawai K; Izumi K; Kumaki M; Ofude M; Zhang J; Keller ET; Namiki M
Prostate; 2012 Dec; 72(16):1789-801. PubMed ID: 22549914
[TBL] [Abstract][Full Text] [Related]
35. Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues.
Chang SS; Reuter VE; Heston WD; Hutchinson B; Grauer LS; Gaudin PB
Cancer; 2000 Jan; 88(2):407-15. PubMed ID: 10640975
[TBL] [Abstract][Full Text] [Related]
36. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
[TBL] [Abstract][Full Text] [Related]
37. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
38. RhoC and guanine nucleotide exchange factor Net1 in androgen-unresponsive mouse mammary carcinoma SC-4 cells and human prostate cancer after short-term endocrine therapy.
Kawata H; Shimada N; Kamiakito T; Komatsu K; Morita T; Ota T; Obayashi M; Shitara K; Tanaka A
Prostate; 2012 Jul; 72(10):1071-9. PubMed ID: 22095553
[TBL] [Abstract][Full Text] [Related]
39. Androgen action in the prostate gland.
Yadav N; Heemers HV
Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
[TBL] [Abstract][Full Text] [Related]
40. The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.
Berruti A; Bollito E; Cracco CM; Volante M; Ciccone G; Porpiglia F; Papotti M; Scarpa RM; Dogliotti L
Prostate; 2010 May; 70(7):718-26. PubMed ID: 20087896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]